PMID- 28234345
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20171116
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 7
IP  - 2
DP  - 2017 Feb 24
TI  - Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.
PG  - e536
LID - 10.1038/bcj.2017.7 [doi]
AB  - CD47, a broadly expressed cell surface protein, inhibits cell phagocytosis via
      interaction with phagocyte-expressed SIRPalpha. A variety of hematological
      malignancies demonstrate elevated CD47 expression, suggesting that CD47 may
      mediate immune escape. We discovered three unique CD47-SIRPalpha blocking
      anti-CD47 monoclonal antibodies (mAbs) with low nano-molar affinity to human and 
      cynomolgus monkey CD47, and no hemagglutination and platelet aggregation
      activity. To characterize the anti-cancer activity elicited by blocking CD47, the
      mAbs were cloned into effector function silent and competent Fc backbones.
      Effector function competent mAbs demonstrated potent activity in vitro and in
      vivo, while effector function silent mAbs demonstrated minimal activity,
      indicating that blocking CD47 only leads to a therapeutic effect in the presence 
      of Fc effector function. A non-human primate study revealed that the effector
      function competent mAb IgG1 C47B222-(CHO) decreased red blood cells (RBC),
      hematocrit and hemoglobin by >40% at 1 mg/kg, whereas the effector function
      silent mAb IgG2sigma C47B222-(CHO) had minimal impact on RBC indices at 1 and 10 
      mg/kg. Taken together, our findings suggest that targeting CD47 is an attractive 
      therapeutic anti-cancer approach. However, the anti-cancer activity observed with
      anti-CD47 mAbs is Fc effector dependent as are the side effects observed on RBC
      indices.
FAU - Pietsch, E C
AU  - Pietsch EC
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Dong, J
AU  - Dong J
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Cardoso, R
AU  - Cardoso R
AD  - Biologics Research, Janssen Research and Development, Spring House, PA, USA.
FAU - Zhang, X
AU  - Zhang X
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Chin, D
AU  - Chin D
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Hawkins, R
AU  - Hawkins R
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Dinh, T
AU  - Dinh T
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Zhou, M
AU  - Zhou M
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Strake, B
AU  - Strake B
AD  - Biologics Research, Janssen Research and Development, Spring House, PA, USA.
FAU - Feng, P-H
AU  - Feng PH
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Rocca, M
AU  - Rocca M
AD  - Biologics Toxicology, Janssen Research and Development, Spring House, PA, USA.
FAU - Santos, C Dos
AU  - Santos CD
AD  - Division of Hematology and Oncology, Department of Medicine, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Shan, X
AU  - Shan X
AD  - Division of Hematology and Oncology, Department of Medicine, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Danet-Desnoyers, G
AU  - Danet-Desnoyers G
AD  - Division of Hematology and Oncology, Department of Medicine, Perelman School of
      Medicine, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Shi, F
AU  - Shi F
AD  - Pharmaceutical Development and Manufacturing Sciences, Janssen Research and
      Development, Malvern, PA, USA.
FAU - Kaiser, E
AU  - Kaiser E
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Millar, H J
AU  - Millar HJ
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Fenton, S
AU  - Fenton S
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Swanson, R
AU  - Swanson R
AD  - Biologics Research, Janssen Research and Development, San Diego, CA, USA.
FAU - Nemeth, J A
AU  - Nemeth JA
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
FAU - Attar, R M
AU  - Attar RM
AD  - Oncology Discovery, Janssen Research and Development, Spring House, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20170224
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD47 Antigen)
RN  - 0 (CD47 protein, human)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - CD47 Antigen/*genetics
MH  - Female
MH  - Humans
MH  - Leukemia/*drug therapy/genetics
MH  - Mice
MH  - Mice, Inbred NOD
PMC - PMC5386341
EDAT- 2017/02/25 06:00
MHDA- 2017/11/07 06:00
CRDT- 2017/02/25 06:00
PHST- 2016/12/16 00:00 [received]
PHST- 2017/01/05 00:00 [accepted]
PHST- 2017/02/25 06:00 [entrez]
PHST- 2017/02/25 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
AID - bcj20177 [pii]
AID - 10.1038/bcj.2017.7 [doi]
PST - epublish
SO  - Blood Cancer J. 2017 Feb 24;7(2):e536. doi: 10.1038/bcj.2017.7.